ライフサイエンスコーパス: Raynaud's phenomenon

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 tom characteristic of dcSSc with and without Raynaud's phenomenon).

2 sure, myopic refractive error (for NTG), and Raynaud's phenomenon.

3 ing significant changes in the management of Raynaud's phenomenon.

4 y hypertension are also showing an effect in Raynaud's phenomenon.

5 occupational origin and a form of secondary Raynaud's phenomenon.

6 anoids are being tested for the treatment of Raynaud's phenomenon.

7 itical digital ischemia) in the treatment of Raynaud's phenomenon all determined improvement of sympt

8 All patients had Raynaud's phenomenon and 82% had gastrointestinal (GI) i

9 er time; features of inflammation as well as Raynaud's phenomenon and esophageal hypomotility diminis

10 gives an update of the current management of Raynaud's phenomenon and its ischaemic complications (di

11 PHT patients had more severe Raynaud's phenomenon and more severe digital tip ulcers,

12 551 and +1922 demonstrated correlations with Raynaud's phenomenon and pulmonary fibrosis, respectivel

13 have been reported into the pathogenesis of Raynaud's phenomenon and the consequences of ischemia.

14 congestive heart failure, stroke, dementia, Raynaud's phenomenon, and all-cause mortality.

15 ancy, she developed multiple autoantibodies, Raynaud's phenomenon, and fetal death occurred at 20 wee

16 linically the condition differs from primary Raynaud's phenomenon as persistent pain and paresthesia

17 discrimination between primary and secondary Raynaud's phenomenon as well as a better way to predict

18 All patients had a history of Raynaud's phenomenon, as well as elevated anticardiolipi

19 Acrocyanosis, Raynaud's phenomenon, chilblain lesions, low-pitch hoars

20 l randomized trials of PDE5Is, patients with Raynaud's phenomenon demonstrated improved blood flow, f

21 New potential targets for treatment of Raynaud's phenomenon derive from experimental observatio

22 CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodact

23 It is characterized by calcinosis cutis, Raynaud's phenomenon, esophageal involvement, sclerodact

24 migraine, coronary spasm, lupus, vasculitis, Raynaud's phenomenon, etc.) in women than men.

25 y is likely to confer benefit in SSc-related Raynaud's phenomenon, further research is required to co

26 (VAS) to evaluate SSc organ system symptoms, Raynaud's phenomenon, gastrointestinal (GI) tract and lu

27 al studies of large cohorts of patients with Raynaud's Phenomenon have addressed the predictors of de

28 uggested that more than one defect may cause Raynaud's phenomenon, including increased alpha-2 sympat

29 Raynaud's phenomenon is characterised by episodic vasosp

30 approach to the management and treatment of Raynaud's phenomenon is emerging.

31 p1 were white women with fatigue, arthritis, Raynaud's phenomenon, malar rash, and photosensitivity.

32 thin 24 months of the onset of the first non-Raynaud's phenomenon manifestation of SSc.

33 ACA was also associated with Raynaud's phenomenon (p = 6.8 x 10(-11)) in RA.

34 d artery stiffness as well as prevalences of Raynaud's phenomenon, pulmonary hypertension, and athero

35 Raynaud's phenomenon (RP) affects 3-9% of the general po

36 d dosage, in 210 patients with lcSSc or with Raynaud's phenomenon (RP) and the presence of SSc-specif

37 Although Raynaud's phenomenon (RP) in adults is frequently report

38 Raynaud's phenomenon (RP) is a common disorder, yet its

39 Raynaud's phenomenon (RP) is a peripheral circulatory di

40 e or absence of 1) lupus skin disease and 2) Raynaud's phenomenon (RP) was determined for each patien

41 imination between patients with SSc, primary Raynaud's phenomenon (RP), and healthy controls.

42 uring recovery from cooling in patients with Raynaud's phenomenon secondary to scleroderma.

43 ing an acute cold challenge in patients with Raynaud's phenomenon secondary to scleroderma.

44 lassified by including the time of the first Raynaud's phenomenon symptom in the definition.

45 ogressive SSc and a more recent onset of non-Raynaud's phenomenon symptoms had higher numbers of mast

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。